How do I buy Entrada Therapeutics, Inc. Common Stock (TRDA) stock?

Buying Entrada Therapeutics, Inc. Common Stock (TRDA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "TRDA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy TRDA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if TRDA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Entrada Therapeutics, Inc. Common Stock (TRDA) Stock

NASDAQ · TRDA

Trade TRDA

5.96

Fundamentals

Market cap

$239.85M

Price / Earnings ratio

-1.5x

Price / Sales ratio

51.7x

Price / Book ratio

1.0x

Return on assets

-42.0%

Ex-Dividend date

N/A

Last payment date

N/A

Dividend amount

$0.00

Dividend yield

0.00%

Debt / Equity ratio

N/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell12 Indicators

Analyst Ratings

Strong Sell0

Sell0

Neutral0

Buy0

Strong Buy0

Financials

Performance

No data available

Debt & Balance Sheet

No data available

Revenue to Profit

No data available

Earnings

No data available

About Entrada Therapeutics, Inc. Common Stock

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

SectorHealthcare

IndustryBiotechnology

Employees152

CEOMr. Dipal Doshi

IPO DateOct 28, 2021

HeadquartersBoston, MA

Key Executives

Name	Title	Year Born
Mr. Dipal Doshi	CEO & Director	1976
Mr. Nathan J. Dowden	President & COO	1971
Dr. Natarajan Sethuraman Ph.D.	President of Research & Development	1962
Mr. Kory James Wentworth CPA	CFO & Treasurer	1979
Dr. Jared Cohen J.D., Ph.D.	General Counsel	—
Ms. Karla MacDonald	Chief Corporate Affairs Officer	—
Mr. Kevin Healy Ph.D.	Senior Vice President of Regulatory Affairs	—
Sandeep Basnet	Head of Information Technology	—

FAQ

Buying Entrada Therapeutics, Inc. Common Stock (TRDA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "TRDA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy TRDA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Entrada Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Entrada Therapeutics, Inc. Common Stock (TRDA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track TRDA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Entrada Therapeutics, Inc. Common Stock (TRDA) Stock

Fundamentals

Recent news

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada's Duchenne drug shown to improve muscle function in early trial

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

New Strong Buy Stocks for December 30th

New Strong Buy Stocks for December 30th

Best Momentum Stocks to Buy for July 9th

Best Momentum Stocks to Buy for July 9th

New Strong Buy Stocks for July 9th

New Strong Buy Stocks for July 9th

Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy

Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

About Entrada Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade